1. Introduction {#sec1-jcm-09-02139}
===============

Cardiovascular disease (CVD) is a multifactorial condition that is the result of a complex interaction between genetic predisposition and well-recognized cardiovascular (CV) risk factors such as diabetes mellitus \[[@B1-jcm-09-02139]\]. Indeed, it is well established that patients with type 2 diabetes mellitus (T2DM) have a two- to four-fold increased risk of atherosclerotic CVD, and they have a poorer prognosis in terms of CV morbidity and mortality than subjects without diabetes \[[@B2-jcm-09-02139]\]. Moreover, in prediabetes, which is not a clinical entity per se but an intermediate metabolic state between normoglycemia and diabetes, there is an increased risk of developing overt T2DM and CVD \[[@B3-jcm-09-02139]\]. This is mainly because it is frequently accompanied by traditional CV risk factors such as obesity, dyslipidemia, and hypertension \[[@B4-jcm-09-02139]\]. Some studies suggest that the development of atherosclerosis begins during the prediabetes state, long before T2DM is established and occurs concurrently with progression from normoglycemia to prediabetes and from prediabetes to overt T2DM \[[@B5-jcm-09-02139]\]. However, since the diagnosis of prediabetes and T2DM is often delayed, macrovascular complications may already be present at the moment of the diagnosis of diabetes \[[@B6-jcm-09-02139]\].

The thickening of the intima-media precedes the development of atherosclerotic plaques, and this interface is well depicted by ultrasound (US) imaging \[[@B7-jcm-09-02139]\]. The measurement of carotid intima-media thickness (c-IMT) through US is a non-invasive method able to detect and quantify subclinical atherosclerosis and atherosclerotic burden in the arterial system \[[@B8-jcm-09-02139]\]. Moreover, US can also identify the presence of carotid artery plaque, which represents later stages of atherosclerosis; carotid artery plaque is an independent predictor of CVD, and its assessment can improve the CVD risk stratification on top of the traditional risk factors \[[@B9-jcm-09-02139]\]. Of note, carotid plaque burden is highly predictive of the development of later CV complications, and the mere presence of carotid plaque is more predictive of adverse CV outcomes than high c-IMT alone \[[@B10-jcm-09-02139],[@B11-jcm-09-02139]\].

We have previously shown that, in subjects with T2DM without clinical CVD, the frequency and burden of subclinical atherosclerotic disease assessed through carotid US is increased compared to nondiabetic subjects \[[@B12-jcm-09-02139]\]. Additionally, prospective US-imaging studies have consistently shown greater severity of carotid atherosclerosis in prediabetic subjects compared to non-diabetic individuals, with reports of increased c-IMT, increased prevalence of carotid plaques, and increased presence of carotid stenosis \[[@B5-jcm-09-02139],[@B13-jcm-09-02139],[@B14-jcm-09-02139],[@B15-jcm-09-02139],[@B16-jcm-09-02139],[@B17-jcm-09-02139],[@B18-jcm-09-02139],[@B19-jcm-09-02139],[@B20-jcm-09-02139]\]. However, apart from the qualitative assessment of the carotid plaque (i.e., present or absent), the quantitative assessment of plaque burden through the number of plaques, plaque thickness, or plaque area has rarely been assessed. This is relevant because each measure may reflect different atherosclerotic phenotypes \[[@B21-jcm-09-02139]\].

Geographical differences in urban vs. rural settings may influence the prevalence of CV risk factors that may be reflected in the prevalence of atherosclerotic plaque. For instance, the risk of long-term coronary heart disease (CHD) is higher in Northern Europe than in Mediterranean Southern Europe for the same levels of cholesterol and systolic blood pressure \[[@B22-jcm-09-02139],[@B23-jcm-09-02139]\]. Moreover, the burden of CV risk factors is higher in rural areas than in urban areas not only in Spain but also in the rest of Europe and in the USA \[[@B24-jcm-09-02139],[@B25-jcm-09-02139],[@B26-jcm-09-02139]\]. Conversely, the prevalence of CHD is lower in Asian populations (in particular in the rural setting) than in Caucasian populations, probably due to a lesser sensitivity to CV risk factors in terms of lifestyle and genetic factors \[[@B27-jcm-09-02139]\].

Based on potential population and geographic differences, we aimed to prospectively assess the prevalence and burden of carotid plaques in prediabetic subjects compared to normoglycemic individuals from a non-urban area in a Mediterranean region that has not been studied previously. For this purpose, we used the Mollerussa cohort, which consists of a representative sample of healthy adults from a local county, the Pla d'Urgell in Catalonia (Spain).

2. Experimental Section {#sec2-jcm-09-02139}
=======================

2.1. Study Population {#sec2dot1-jcm-09-02139}
---------------------

The Mollerussa study is a prospective observational cohort study that was conducted between August 2011 and July 2015 in a non-urban area of Catalonia (Spain) among subjects from the general population. Details of the study and the protocol have been described previously \[[@B28-jcm-09-02139],[@B29-jcm-09-02139]\]. Briefly, the study randomly selected 2226 subjects ≥25 years of age who were attended by any of the Primary Healthcare centers in the area of Pla d'Urgell (Catalonia, Spain). Subjects with a previous diagnosis of diabetes (T1, T2, or any specific subtype), treated with oral glucose-lowering drugs, or metformin for other conditions were excluded. Moreover, the study excluded subjects who had CVD (i.e., a diagnosis of heart disease, heart failure, and aortic stenosis), or who were considered to have hypertension or dyslipidemia (i.e., if they were using anti-hypertensive or lipid-lowering medications). Out of the 594 subjects initially recruited based on their willingness to participate, fulfillment of inclusion criteria, and availability of baseline glycemia measurements, the study finally assessed 583 individuals. This study included the initial cohort with available US-imaging data (*n* = 550). The study protocol was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the Primary Health Care University Research Institute (IDIAP) Jordi Gol (P12/043). An informed consent form was signed for all the study participants.

2.2. Measures and Data Collection {#sec2dot2-jcm-09-02139}
---------------------------------

As previously described, data on sociodemographic variables and anthropometric measures were recorded at baseline \[[@B28-jcm-09-02139]\]. Moreover, laboratory parameters were obtained, and patients were classified into two groups based on glycemic status according to the fasting plasma glucose (FPG) and glycated hemoglobin (A1C) ADA criteria \[[@B30-jcm-09-02139]\]: (1) normal glucose tolerance (NGT) group, namely subjects with FPG \<100 mg/dL (\<5.6 mmol/L) and/or A1C \<5.7%, and (2) prediabetes group, including those with FPG between 100 mg/dL and \<126 mg/dL (5.6--6.9 mmol/L) and/or A1C between 5.7% and \<6.5%. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula as described previously \[[@B29-jcm-09-02139]\].

Each study participant underwent a US study conducted by the multidisciplinary Unit for Detection and Treatment of Atherothrombotic Disease (UDETMA) from the Hospital Universitari Arnau de Vilanova (Lleida, Spain). The US was used to assess both carotids to measure c-IMT and carotid plaques following the standardized operational procedure and the Mannheim consensus \[[@B7-jcm-09-02139]\]. This included a cross-sectional view of the common, bulb, and internal segments of both carotid arteries (CCA, BC, and ICA, respectively). In addition, atheromatous carotid plaque was defined as a focal encroachment into the arterial lumen, with online average c-IMT values in these three areas above 1.5 mm considered plaques \[[@B31-jcm-09-02139]\].

2.3. Statistical Analysis {#sec2dot3-jcm-09-02139}
-------------------------

Descriptive data are presented as the mean and standard deviation (SD) for continuous outcomes, or number and percentage (%) for categorical outcomes. Student's t-test and analysis of variance (ANOVA) were used to analyze the differences of means between the different groups. Chi-square test was used for categorical outcomes. We performed multivariate linear and logistic regression models adjusting for sex, age, tobacco exposure, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, systolic and diastolic blood pressure, waist as a measure of adiposity, urate, kidney function as eGFR and leukocytes to determine the predictors of c-IMT and carotid plaques, respectively. All significance tests were 2-tailed, and values of *p* \< 0.05 were considered significant. All analyses were conducted using the Bioconductor package of the free R statistical programming language version 3.3.1 \[[@B32-jcm-09-02139]\].

3. Results {#sec3-jcm-09-02139}
==========

Overall, 40.7% patients were diagnosed as having prediabetes (*n* = 224) and 59.3% (*n* = 326) NGT. The main characteristics of each group are shown in [Table 1](#jcm-09-02139-t001){ref-type="table"}. There were no significant differences in the proportion of men/women between groups, but subjects with prediabetes were older and had a poorer CV risk profile in terms of adiposity (*p* \< 0.001), dyslipidemia and hypertension (*p* = 0.002), tobacco exposure and kidney function (*p* \< 0.001). In addition, the leukocyte count was higher in the prediabetic group (*p* = 0.033).

3.1. Carotid-IMT and Plaque Burden {#sec3dot1-jcm-09-02139}
----------------------------------

The mean c-IMT in the total cohort was 0.69 mm (SD = 0.1), and it was significantly higher in the prediabetes group compared to the NGT group (0.72 vs. 0.67 mm, *p* \< 0.001, [Table 2](#jcm-09-02139-t002){ref-type="table"}). The overall prevalence of atherosclerotic carotid plaque was 27.1%, and it was present in a higher proportion of subjects with prediabetes than in the NGT group (37.9% vs. 19.6%, *p* \< 0.001). In the overall population, 14% of individuals had one plaque, while 13.1% had multiple plaques ([Table 2](#jcm-09-02139-t002){ref-type="table"}). This percentage also varied according to the glycemic status, with a higher proportion of subjects with one or multiple plaques in the prediabetes group (19.6% and 18.3%, respectively) than in the NGT group (10.1% and 9.5%, respectively, *p* \< 0.001, [Table 2](#jcm-09-02139-t002){ref-type="table"}).

3.2. Predictors of c-IMT and Atherosclerotic Plaque Burden {#sec3dot2-jcm-09-02139}
----------------------------------------------------------

The linear regression analysis for the predictors of c-IMT revealed that the only variables associated with increased thickness were male gender (*p* \< 0.001), older age (*p* \< 0.001), and elevated systolic blood pressure (*p* = 0.007), but not prediabetes ([Table 3](#jcm-09-02139-t003){ref-type="table"}). The logistic regression analysis (after controlling for conventional atherosclerotic risk factors) showed that the presence of any carotid plaque was associated with prediabetes (OR = 1.64, *p* = 0.034), male gender (OR = 1.94, *p* = 0.026), older age (OR = 1.08, *p* \< 0.001), tobacco exposure (OR = 1.70, *p* = 0.036), LDL-cholesterol (OR = 1.01, *p* = 0.013), and leukocyte count (OR = 1.18, *p* = 0.022) ([Table 4](#jcm-09-02139-t004){ref-type="table"}). Further information on the univariate analysis of carotid plaque presence is shown in [Table S1](#app1-jcm-09-02139){ref-type="app"}.

4. Discussion {#sec4-jcm-09-02139}
=============

Our study reveals that subjects with prediabetes from a non-urban population had an increased c-IMT and prevalence and burden of carotid plaques compared to NGT subjects. However, although prediabetes was not correlated with c-IMT, this entity was an independent predictor of plaque burden. Considering that carotid plaque is in turn an independent predictor of CVD, our data suggest that, in our study population, almost 38% of patients with prediabetes are at a very high risk of developing CVD.

The mean c-IMT difference between subjects with prediabetes and subjects with normoglycemia reported by a meta-analysis of 13 studies using US imaging was 0.04 mm (SD, 0.012--0.048) \[[@B13-jcm-09-02139]\]. This figure has been confirmed in further studies, and it is also in line with the difference observed in our study (0.05 mm) \[[@B14-jcm-09-02139],[@B15-jcm-09-02139],[@B16-jcm-09-02139],[@B18-jcm-09-02139]\]. Regarding carotid plaques, our research found that the prevalence was 38% among subjects with IGT and 20% in the NGT group. These figures agree, albeit in a low range, with the prevalence reported by similar US imaging studies that incorporated carotid plaque assessment in addition to c-IMT, ranging between 25--45% in IGT subjects and between 21--34% in NGT subjects \[[@B15-jcm-09-02139],[@B16-jcm-09-02139],[@B17-jcm-09-02139],[@B33-jcm-09-02139]\].

The frequency of CV risk factors varies between populations and geographical areas \[[@B22-jcm-09-02139],[@B23-jcm-09-02139],[@B24-jcm-09-02139],[@B25-jcm-09-02139],[@B26-jcm-09-02139],[@B27-jcm-09-02139]\]. In our study, the first to be conducted in a Mediterranean non-urban area, the prevalence of carotid plaque in prediabetes was lower than that observed in two other studies conducted in an urban area or in general population of Southern European regions (38% vs. 45--49%) \[[@B16-jcm-09-02139],[@B20-jcm-09-02139]\]. In contrast, the reported frequency in urban areas of Japan and China was higher than that in our study (24--28% vs. 38%) \[[@B5-jcm-09-02139],[@B15-jcm-09-02139],[@B17-jcm-09-02139],[@B33-jcm-09-02139],[@B34-jcm-09-02139]\]. These differences match previous epidemiologic studies of a lower CV risk profile in Asian populations, but do not agree with the higher frequency reported in rural vs. urban areas in Caucasian populations. This apparent discrepancy could be explained by methodological differences between studies, including the characteristics of the studied population and/or of the carotid US measures assessed. Regarding the study population, we included subjects younger than those of previous similar studies (mean age 50 years in our study vs. 57--68 years in others), which may be clearly associated with a lower CV risk in our case. Moreover, and most importantly, our study was conducted on subjects from the general population a priori free of CVD, while reports assessing individuals with CV risk factors or established CVD observed a much higher prevalence of carotid plaques in both control and prediabetic groups (44--53% and 49--79%, respectively) \[[@B5-jcm-09-02139],[@B17-jcm-09-02139],[@B20-jcm-09-02139],[@B34-jcm-09-02139]\]. Regarding differences in US measurements, the definition of carotid plaque frequently varies between studies. For instance, the use of less strict criteria to consider carotid plaque might have resulted in lower sensitivity for the diagnosis of carotid plaque, which could have led to a higher number of subjects being classified as plaque-free in some studies \[[@B15-jcm-09-02139],[@B33-jcm-09-02139]\]. Overall, and despite methodological differences, independent US imaging studies confirm our results that carotid plaque burden (both presence and number of plaques) is increased among subjects with prediabetes compared with those with normoglycemia. This is also in agreement with studies conducted using magnetic resonance (MRI), which have found a prevalence between 16--18% in control subjects and 33--35% in subjects with prediabetes \[[@B35-jcm-09-02139],[@B36-jcm-09-02139]\].

In our study, older age, male gender, and increased systolic blood pressure were positively correlated with c-IMT and older age and male gender were independent predictors of plaque presence. Additionally, prediabetes and LDL-cholesterol levels were not correlated with c-IMT, but they were predictors of the presence of plaque together with tobacco exposure. The same variables have been previously shown as predictors of c-IMT and the same ones as predictors of the presence of carotid plaque in different populations \[[@B37-jcm-09-02139],[@B38-jcm-09-02139]\], including those assessing subjects with prediabetes \[[@B5-jcm-09-02139],[@B16-jcm-09-02139],[@B18-jcm-09-02139],[@B19-jcm-09-02139],[@B20-jcm-09-02139]\]. These results may reflect the fact that, although c-IMT and plaque are correlated processes, they capture the impact of different factors; in actuality, c-IMT may reverse to normal values as a result of improvements in some factors. Indeed, while age and hypertension are primary contributors to c-IMT, thickening, age and dyslipidemia are the main predictors of carotid plaque \[[@B21-jcm-09-02139],[@B39-jcm-09-02139]\]. Adding to these differences, our study showed that increased leukocytes independently predicted the presence of plaque but was not related to increased c-IMT. Atherosclerosis is a chronic inflammatory disease, and plaque a localized manifestation of it where leukocyte recruitment, oxidation, endothelial dysfunction, and/or smooth cell proliferation are involved \[[@B40-jcm-09-02139]\]. Indeed, epidemiological studies have shown a positive correlation between white blood cell (WBC) count and the risk of CVD in subjects with or without CVD \[[@B41-jcm-09-02139]\]. Moreover, WBC count is positively correlated with A1C levels, and elevated count has been associated with carotid and aortic plaque thickness in subclinical atherosclerosis \[[@B42-jcm-09-02139],[@B43-jcm-09-02139],[@B44-jcm-09-02139]\]. Finally, low-grade chronic inflammation is a key component of T2DM, where an increased WBC count has been reported as independently associated with increased incidence and risk of the disease \[[@B45-jcm-09-02139],[@B46-jcm-09-02139]\]. Of note, WBC counts have also been reported to be higher in subjects with IGT than in normoglycemic subjects \[[@B47-jcm-09-02139],[@B48-jcm-09-02139]\], as also observed in our study. It is therefore possible that elevated leukocyte count in subjects with prediabetes may be an early marker of disease and of initiation or progression of significant atherosclerotic plaques, in turn leading to an increased risk of CVD.

Although it is beyond dispute that subjects with prediabetes are at increased risk for CVD, it remains unclear whether screening for subclinical atherosclerosis in this subpopulation is appropriate. The confirmation that the proportion of carotid plaques is higher among these individuals than in normoglycemic subjects is relevant in daily clinical practice for several reasons. Firstly, because some clinical trials on new antidiabetic treatments (e.g., dipeptidyl peptidase-4 inhibitors; DPP-4) have shown to attenuate c-IMT progression compared with conventional treatment in subjects with T2DM and no CVD \[[@B21-jcm-09-02139]\]. Secondly, because of the evidence that CV mortality in people with IGT is statistically lower if they undergo lifestyle intervention instead of being treated as per standard of care \[[@B49-jcm-09-02139]\]. Considering all of the evidence, it would seem appropriate to identify subjects with prediabetes with associated subclinical atherosclerosis in daily clinical practice to enforce more stringent CV prevention strategies for them.

This study has some strengths and limitations worth mentioning. The main strength is the prospective, population-based design, which reflects real-world data from a non-urban area not previously studied. Moreover, it was specifically designed to detect prediabetes and, besides the careful evaluation of traditional CV risk factors, the US carotid imaging was based on standardized clinical procedures, conducted by trained staff, and included the plaque burden in the c-IMT measurements. One limitation of the study is that the FPG and A1C tests were performed only once, and we did not conduct the oral glucose tolerance test (OGTT) as a criterion for prediabetes definition. The latter is because OGTT is less accessible than FPG or A1C in clinical practice, has low reproducibility, and is inconvenient in terms of costs and time consumption \[[@B50-jcm-09-02139]\]. However, while all three glycemic indices (A1C, FPG, and OGTT) have been shown to predict c-IMT, only FPG seems to predict the presence of carotid plaques \[[@B15-jcm-09-02139]\]. Another limitation is that the design of the Mollerussa Cohort Study was focused on the evaluation of different primary endpoints, i.e., the prevalence of prediabetes and undiagnosed diabetes in that particular population. Furthermore, the current study may not have sufficient power to detect the contribution of some risk factors, such as LDL, to c-IMT thickening. In addition, prospective studies are needed to properly address the contribution of all CV risk factors to the progression of atherosclerotic disease.

5. Conclusions {#sec5-jcm-09-02139}
==============

The results of this observational study support that, in subjects from a non-urban Mediterranean area, prediabetes predicts the presence of atherosclerotic plaques as measured by US-imaging. This is relevant for identifying individuals at a high risk of subclinical atherosclerotic disease, who could benefit from intensive preventive treatment before clinical CVD appears.
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The following are available online at <https://www.mdpi.com/2077-0383/9/7/2139/s1>, Table S1: Univariate analysis of for the presence of plaque presence in the whole study group.
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jcm-09-02139-t001_Table 1

###### 

Sociodemographic and clinical characteristics of the subjects included in the study.

                                      All Subjects   NGT            Prediabetes    *p*-Value
  ----------------------------------- -------------- -------------- -------------- -----------
  Sample size, N (%)                  550            326 (59.3%)    224 (40.7%)    
  Gender (women), n (%)               321 (58.4)     190 (58.3)     131 (58.5)     0.963
  Age (years), mean (SD)              50.1 (13)      47.3 (12.8)    54.3 (12.2)    \<0.001
  BMI (kg/m^2^), mean (SD)            26.1 (4.5)     25.3 (4.3)     27.3 (4.5)     \<0.001
  Waist (cm), mean (SD)               93.8 (12.2)    91.8 (12.0)    96.7 (12.0)    \<0.001
  Tobacco exposure, n (%)             283 (51.5%)    162 (49.7%)    121 (54%)      \<0.001
  FPG (mg/dL), mean (SD)              90.8 (10.3)    86.6 (7.0)     97 (11.2)      \<0.001
  A1C (%), mean (SD)                  5.5 (0.4)      5.2 (0.3)      5.8 (0.3)      \<0.001
  Dyslipidemia, n (%)                 65 (11.8%)     27 (8.3%)      38 (17%)       0.002
  Total-c (mg/dL), mean (SD)          201 (36.2)     197.8 (38.3)   205.7 (32.4)   0.006
  HDL-c (mg/dL), mean (SD)            58.7 (14.7)    58.7 (14.8)    58.8 (14.4)    0.911
  LDL-c (mg/dL), mean (SD)            122 (30.7)     119.4 (31.3)   125.6 (29.4)   0.010
  Triglycerides (mg/dL), mean (SD)    107.2 (80.9)   104.5 (90.8)   111 (63.7)     0.070
  Hypertension (%), n (%)             84 (15.3)      37 (11.3)      47 (21)        0.002
  SBP (mmHg), mean (SD)               122 (16.7)     119.2 (16.3)   125.9 (16.5)   \<0.001
  DBP (mmHg), mean (SD)               76.8 (10.1)    75.7 (10.1)    78.4 (9.9)     0.001
  Creatinine (mg/dL), mean (SD)       0.8 (0.2)      0.8 (0.2)      0.8 (0.2)      0.412
  eGFR (ml/min), mean (SD)            94.2 (15.1)    96.7 (14.1)    90.6 (15.8)    \<0.001
  Serum urate (mg/dL), mean (SD)      4.9 (1.3)      4.8 (1.2)      5 (1.3)        0.056
  ALT (U/L), mean (SD)                20.4 (17.4)    20.4 (20.5)    20.3 (11.5)    0.190
  Leukocytes (× 10^9^/L), mean (SD)   6.6 (1.7)      6.4 (1.6)      6.8 (1.8)      0.033

A1C, glycated hemoglobin; ALT, alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; NGT, normal glucose tolerance; SBP, systolic blood pressure; SD, standard deviation; Total-c, total cholesterol.

jcm-09-02139-t002_Table 2

###### 

Carotid intima-media thickness (c-IMT) and plaque burden among patients with prediabetes or normal glucose tolerance.

                                      All Subjects   NGT          Prediabetes   *p*-Value
  ----------------------------------- -------------- ------------ ------------- -----------
  c-IMT, mm, mean (SD)                0.69 (0,1)     0.67 (0.1)   0.72 (0.1)    \<0.001
  Presence of carotid plaque, n (%)                                             
  No plaque                           401 (72.9)     262 (80.4)   139 (62.1)    \<0.001
  Significant plaque                  149 (27.1)     64 (19.6)    85 (37.9)     \<0.001
  *Subjects with 1 plaque*            77 (14)        33 (10.1)    44 (19.6)     \<0.001
  *Subjects with multiple plaques*    72 (13.1)      31 (9.5)     41 (18.3)     \<0.001
  Number of carotid plaques                                                     
  Mean (SD)                           0.47 (0.9)     0.36 (0.9)   0.64 (1.0)    \<0.001
  Median (IQR)                        0 (0--1)       0 (0--0)     0 (0--1)      

c-IMT, carotid intima-media thickness; IQR, interquartile range; NGT, normal glucose tolerance; SD, standard deviation.

jcm-09-02139-t003_Table 3

###### 

Linear regression analysis for the predictors of c-IMT.

                             Coefficient   95% CI        *p*-Value
  -------------------------- ------------- ------------- -----------
  Prediabetes                0.47          −1.23--2.17   0.589
  Gender, male               3.99          1.85--6.14    \<0.001
  Age                        0.47          0.38--0.56    \<0.001
  Tobacco exposure           1.31          −0.38--3.00   0.128
  Waist                      0.01          −0.07--0.10   0.738
  LDL cholesterol            0.03          −0.00--0.05   0.067
  HDL cholesterol            −0.02         −0.08--0.05   0.645
  Triglycerides              0.00          −0.01--0.01   0.976
  eGFR                       −0.04         −0.11--0.03   0.244
  Leukocytes                 −0.11         −0.62--0.41   0.683
  Serum urate                −0.13         −1.01--0.75   0.770
  Systolic blood pressure    0.11          0.03--0.19    0.007
  Diastolic blood pressure   −0.08         −0.20--0.04   0.206

CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimate glomerular filtration rate.

jcm-09-02139-t004_Table 4

###### 

Logistic regression analysis for the predictors of carotid plaques.

                             OR     95% CI       *p*-Value
  -------------------------- ------ ------------ -----------
  Prediabetes                1.64   1.04--2.58   0.034
  Gender, male               1.94   1.09--3.49   0.026
  Age                        1.08   1.06--1.11   \<0.001
  Tobacco exposure           1.70   1.04--2.81   0.036
  Waist                      1.02   0.99--1.04   0.216
  LDL cholesterol            1.01   1.00--1.02   0.013
  HDL cholesterol            1.00   0.98--1.02   0.969
  Triglycerides              1.00   0.10--1.00   0.580
  eGFR                       1.01   0.99--1.03   0.574
  Leukocytes                 1.18   1.03--1.37   0.022
  Serum urate                0.95   0.75--1.21   0.696
  Systolic blood pressure    1.02   0.99--1.04   0.158
  Diastolic blood pressure   0.10   0.96--1.03   0.811

OR, odds ratio; CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate.

[^1]: These authors contributed equally to this study.
